Drug data last refreshed 4h ago · AI intelligence enriched 6d ago
ALEVE-D SINUS & COLD is a combination OTC tablet containing naproxen sodium (an NSAID) and pseudoephedrine hydrochloride (a decongestant) in extended-release formulation. It treats symptoms of sinus congestion, cold, and associated pain/inflammation by reducing inflammation and clearing nasal passages. The product targets adults seeking multi-symptom cold and sinus relief in a single dosage form.
Product approaching loss of exclusivity with moderate competitive pressure (30%), signaling potential team restructuring and transition planning for downstream portfolio.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on ALEVE-D SINUS & COLD offers limited growth trajectory due to LOE approaching status, but provides solid experience in OTC commercial execution, defensive marketing, and generic transition management. Roles focus on maximizing profitability before generic entry rather than market expansion, making this suitable for professionals seeking operational efficiency and transition management experience.
Worked on ALEVE-D SINUS & COLD at Bayer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.